Elite in Childhood Pancreatitis

Dr. Melvin B. Heyman

Pediatrics | Gastroenterology
500 Parnassus Ave, 
San Francisco, CA 
Elite in Childhood Pancreatitis
500 Parnassus Ave, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melvin Heyman is a Pediatrics specialist and a Gastroenterologist in San Francisco, California. Dr. Heyman is rated as an Elite provider by MediFind in the treatment of Childhood Pancreatitis. His top areas of expertise are Childhood Pancreatitis, Chronic Pancreatitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles in the study of Childhood Pancreatitis.

Specialties
Pediatrics
Gastroenterology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

500 Parnassus Ave, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

140 Total Publications

Parents with physical disabilities and their parenting experiences: a scoping review of qualitative studies.
Parents with physical disabilities and their parenting experiences: a scoping review of qualitative studies.
Journal: Disability and rehabilitation
Published: August 25, 2025
Similar Doctors
Elite in Childhood Pancreatitis
Dr. Emily R. Perito
Pediatric Gastroenterology | Gastroenterology | Pediatrics
Elite in Childhood Pancreatitis
Dr. Emily R. Perito
Pediatric Gastroenterology | Gastroenterology | Pediatrics
500 Parnassus Ave University Of California San Francisc, Mu408e, Box 0136 Pediatric Gastroenterology, 
San Francisco, CA 
 (0.1 miles away)
415-476-5892
Languages Spoken:
English
See accepted insurances

Emily Perito is a Pediatric Gastroenterologist and a Gastroenterologist in San Francisco, California. Dr. Perito is rated as a Distinguished provider by MediFind in the treatment of Childhood Pancreatitis. Her top areas of expertise are Childhood Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Liver Transplant, and Gallbladder Removal.

Elite in Childhood Pancreatitis
Dr. Sohail Z. Husain
Pediatric Gastroenterology | Pediatrics
Elite in Childhood Pancreatitis
Dr. Sohail Z. Husain
Pediatric Gastroenterology | Pediatrics
725 Welch Rd, 
Palo Alto, CA 
 (27.5 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Sohail Husain is a Pediatric Gastroenterologist and a Pediatrics provider in Palo Alto, California. Dr. Husain is rated as a Distinguished provider by MediFind in the treatment of Childhood Pancreatitis. His top areas of expertise are Childhood Pancreatitis, Hereditary Pancreatitis, Acute Pancreatitis, Endoscopy, and Gallbladder Removal.

Elite in Childhood Pancreatitis
Dr. Zachary M. Sellers
Pediatric Gastroenterology | Pediatrics
Elite in Childhood Pancreatitis
Dr. Zachary M. Sellers
Pediatric Gastroenterology | Pediatrics
750 Welch Rd, Suite 116, 
Palo Alto, CA 
 (27.3 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Zachary Sellers is a Pediatric Gastroenterologist and a Pediatrics provider in Palo Alto, California. Dr. Sellers is rated as a Distinguished provider by MediFind in the treatment of Childhood Pancreatitis. His top areas of expertise are Childhood Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Exocrine Pancreatic Insufficiency, and Gallbladder Removal.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heyman's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile